Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys
Identifieur interne : 000800 ( PascalFrancis/Checkpoint ); précédent : 000799; suivant : 000801Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys
Auteurs : Pershia Samadi [Canada] ; Laurent Gregoire [Canada] ; Arash Rassoulpour [États-Unis] ; Paolo Guidetti [Canada] ; Emanuela Izzo [Italie] ; Robert Schwarcz [États-Unis] ; Paul J. Bedard [Canada]Source :
- Movement disorders [ 0885-3185 ] ; 2005.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Singe.
English descriptors
- KwdEn :
Abstract
Homeostatic interactions between dopamine and glutamate are central to the normal physiology of the basal ganglia. This relationship is altered in Parkinsonism and in levodopa-induced dyskinesias (LID), resulting in an upregulation of corticostriatal glutamalergic function. Kynurenic acid (KYNA), a tryptophan metabolite with antagonist activity at ionotropic glutamate receptors and the capability to inhibit glutamate release presynaplically, might therefore be of therapeutic value in LID. To evaluate this hypothesis, we used a pharmacological tool, the kynurenine 3-hydroxylase inhibitor Ro 61-8048, which raises KYNA levels acutely. Ro 61-8048 was tested in MPTP cynomolgus monkeys with a stable parkinsonian syndrome and reproducible dyskinesias after each dose of levodopa. Serum and CSF concentrations of KYNA and its precursor kynurenine increased dose-dependently after Ro 61-8048 administration, alone or in combination with levodopa. Coadministration of Ro 61-8048 with levodopa produced a moderate but significant reduction in the severity of dyskinesias while maintaining the motor benefit. These results suggest that elevation of KYNA levels through inhibition of kynurenine 3-hydroxylase constitutes a promising novel approach for managing LID in Parkinson's disease.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:05-0387176Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys</title><author><name sortKey="Samadi, Pershia" sort="Samadi, Pershia" uniqKey="Samadi P" first="Pershia" last="Samadi">Pershia Samadi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Québec</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Département de Medicine, Université Laval</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Gregoire, Laurent" sort="Gregoire, Laurent" uniqKey="Gregoire L" first="Laurent" last="Gregoire">Laurent Gregoire</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Québec</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Rassoulpour, Arash" sort="Rassoulpour, Arash" uniqKey="Rassoulpour A" first="Arash" last="Rassoulpour">Arash Rassoulpour</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Maryland Psychiatric Research Center, University of Maryland School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Guidetti, Paolo" sort="Guidetti, Paolo" uniqKey="Guidetti P" first="Paolo" last="Guidetti">Paolo Guidetti</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Québec</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Izzo, Emanuela" sort="Izzo, Emanuela" uniqKey="Izzo E" first="Emanuela" last="Izzo">Emanuela Izzo</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Newron Pharmaceuticals</s1><s2>Bresso</s2><s3>ITA</s3><sZ>5 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Newron Pharmaceuticals</wicri:noRegion></affiliation></author><author><name sortKey="Schwarcz, Robert" sort="Schwarcz, Robert" uniqKey="Schwarcz R" first="Robert" last="Schwarcz">Robert Schwarcz</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Maryland Psychiatric Research Center, University of Maryland School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Québec</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Département de Medicine, Université Laval</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">05-0387176</idno><date when="2005">2005</date><idno type="stanalyst">PASCAL 05-0387176 INIST</idno><idno type="RBID">Pascal:05-0387176</idno><idno type="wicri:Area/PascalFrancis/Corpus">000892</idno><idno type="wicri:Area/PascalFrancis/Curation">000431</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000800</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000800</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys</title><author><name sortKey="Samadi, Pershia" sort="Samadi, Pershia" uniqKey="Samadi P" first="Pershia" last="Samadi">Pershia Samadi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Québec</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Département de Medicine, Université Laval</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Gregoire, Laurent" sort="Gregoire, Laurent" uniqKey="Gregoire L" first="Laurent" last="Gregoire">Laurent Gregoire</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Québec</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Rassoulpour, Arash" sort="Rassoulpour, Arash" uniqKey="Rassoulpour A" first="Arash" last="Rassoulpour">Arash Rassoulpour</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Maryland Psychiatric Research Center, University of Maryland School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Guidetti, Paolo" sort="Guidetti, Paolo" uniqKey="Guidetti P" first="Paolo" last="Guidetti">Paolo Guidetti</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Québec</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec</wicri:noRegion></affiliation></author><author><name sortKey="Izzo, Emanuela" sort="Izzo, Emanuela" uniqKey="Izzo E" first="Emanuela" last="Izzo">Emanuela Izzo</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Newron Pharmaceuticals</s1><s2>Bresso</s2><s3>ITA</s3><sZ>5 aut.</sZ></inist:fA14><country>Italie</country><wicri:noRegion>Newron Pharmaceuticals</wicri:noRegion></affiliation></author><author><name sortKey="Schwarcz, Robert" sort="Schwarcz, Robert" uniqKey="Schwarcz R" first="Robert" last="Schwarcz">Robert Schwarcz</name><affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Maryland Psychiatric Research Center, University of Maryland School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>6 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Québec</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Département de Medicine, Université Laval</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>7 aut.</sZ></inist:fA14><country>Canada</country><wicri:noRegion>Québec</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Movement disorders</title><title level="j" type="abbreviated">Mov. disord.</title><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term><term>Dyskinesia</term><term>Glutamate</term><term>Kynurenine 3-monooxygenase</term><term>Levodopa</term><term>Monkey</term><term>Nervous system diseases</term><term>Parkinson disease</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term><term>Parkinson maladie</term><term>Dyskinésie</term><term>Kynurenine 3-monooxygenase</term><term>Lévodopa</term><term>Animal</term><term>Singe</term><term>Glutamate</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Singe</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Homeostatic interactions between dopamine and glutamate are central to the normal physiology of the basal ganglia. This relationship is altered in Parkinsonism and in levodopa-induced dyskinesias (LID), resulting in an upregulation of corticostriatal glutamalergic function. Kynurenic acid (KYNA), a tryptophan metabolite with antagonist activity at ionotropic glutamate receptors and the capability to inhibit glutamate release presynaplically, might therefore be of therapeutic value in LID. To evaluate this hypothesis, we used a pharmacological tool, the kynurenine 3-hydroxylase inhibitor Ro 61-8048, which raises KYNA levels acutely. Ro 61-8048 was tested in MPTP cynomolgus monkeys with a stable parkinsonian syndrome and reproducible dyskinesias after each dose of levodopa. Serum and CSF concentrations of KYNA and its precursor kynurenine increased dose-dependently after Ro 61-8048 administration, alone or in combination with levodopa. Coadministration of Ro 61-8048 with levodopa produced a moderate but significant reduction in the severity of dyskinesias while maintaining the motor benefit. These results suggest that elevation of KYNA levels through inhibition of kynurenine 3-hydroxylase constitutes a promising novel approach for managing LID in Parkinson's disease.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0></fA01><fA03 i2="1"><s0>Mov. disord.</s0></fA03><fA05><s2>20</s2></fA05><fA06><s2>7</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys</s1></fA08><fA11 i1="01" i2="1"><s1>SAMADI (Pershia)</s1></fA11><fA11 i1="02" i2="1"><s1>GREGOIRE (Laurent)</s1></fA11><fA11 i1="03" i2="1"><s1>RASSOULPOUR (Arash)</s1></fA11><fA11 i1="04" i2="1"><s1>GUIDETTI (Paolo)</s1></fA11><fA11 i1="05" i2="1"><s1>IZZO (Emanuela)</s1></fA11><fA11 i1="06" i2="1"><s1>SCHWARCZ (Robert)</s1></fA11><fA11 i1="07" i2="1"><s1>BEDARD (Paul J.)</s1></fA11><fA14 i1="01"><s1>Centre de Recherche en Neurosciences, Centre Hospitalier Universitaire de Québec</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>7 aut.</sZ></fA14><fA14 i1="02"><s1>Département de Medicine, Université Laval</s1><s2>Québec</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>7 aut.</sZ></fA14><fA14 i1="03"><s1>Maryland Psychiatric Research Center, University of Maryland School of Medicine</s1><s2>Baltimore, Maryland</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>6 aut.</sZ></fA14><fA14 i1="04"><s1>Newron Pharmaceuticals</s1><s2>Bresso</s2><s3>ITA</s3><sZ>5 aut.</sZ></fA14><fA20><s1>792-802</s1></fA20><fA21><s1>2005</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>20953</s2><s5>354000132363110030</s5></fA43><fA44><s0>0000</s0><s1>© 2005 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>66 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>05-0387176</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Movement disorders</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Homeostatic interactions between dopamine and glutamate are central to the normal physiology of the basal ganglia. This relationship is altered in Parkinsonism and in levodopa-induced dyskinesias (LID), resulting in an upregulation of corticostriatal glutamalergic function. Kynurenic acid (KYNA), a tryptophan metabolite with antagonist activity at ionotropic glutamate receptors and the capability to inhibit glutamate release presynaplically, might therefore be of therapeutic value in LID. To evaluate this hypothesis, we used a pharmacological tool, the kynurenine 3-hydroxylase inhibitor Ro 61-8048, which raises KYNA levels acutely. Ro 61-8048 was tested in MPTP cynomolgus monkeys with a stable parkinsonian syndrome and reproducible dyskinesias after each dose of levodopa. Serum and CSF concentrations of KYNA and its precursor kynurenine increased dose-dependently after Ro 61-8048 administration, alone or in combination with levodopa. Coadministration of Ro 61-8048 with levodopa produced a moderate but significant reduction in the severity of dyskinesias while maintaining the motor benefit. These results suggest that elevation of KYNA levels through inhibition of kynurenine 3-hydroxylase constitutes a promising novel approach for managing LID in Parkinson's disease.</s0></fC01><fC02 i1="01" i2="X"><s0>002B17</s0></fC02><fC02 i1="02" i2="X"><s0>002B02B06</s0></fC02><fC02 i1="03" i2="X"><s0>002B02U01</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Dyskinésie</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Dyskinesia</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Disquinesia</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Kynurenine 3-monooxygenase</s0><s2>FE</s2><s5>09</s5><s6>Kynurenine «3»-monooxygenase</s6></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Kynurenine 3-monooxygenase</s0><s2>FE</s2><s5>09</s5><s6>Kynurenine «3»-monooxygenase</s6></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Kynurenine 3-monooxygenase</s0><s2>FE</s2><s5>09</s5><s6>Kynurenine «3»-monooxygenase</s6></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Lévodopa</s0><s2>NK</s2><s2>FR</s2><s5>10</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Levodopa</s0><s2>NK</s2><s2>FR</s2><s5>10</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Levodopa</s0><s2>NK</s2><s2>FR</s2><s5>10</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Animal</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Animal</s0><s5>11</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Animal</s0><s5>11</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Singe</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Monkey</s0><s5>12</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Mono</s0><s5>12</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Glutamate</s0><s2>NK</s2><s2>FX</s2><s5>13</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Glutamate</s0><s2>NK</s2><s2>FX</s2><s5>13</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Glutamato</s0><s2>NK</s2><s2>FX</s2><s5>13</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Oxidoreductases</s0><s2>FE</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Oxidoreductases</s0><s2>FE</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Oxidoreductases</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Enzima</s0><s2>FE</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Primates</s0><s2>NS</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Primates</s0><s2>NS</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Primates</s0><s2>NS</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Encéphale pathologie</s0><s5>37</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>37</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>37</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0><s5>38</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0><s5>38</s5></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>39</s5></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>39</s5></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>39</s5></fC07><fC07 i1="09" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0><s5>40</s5></fC07><fC07 i1="09" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>40</s5></fC07><fC07 i1="09" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>40</s5></fC07><fC07 i1="10" i2="X" l="FRE"><s0>Mouvement involontaire</s0><s5>41</s5></fC07><fC07 i1="10" i2="X" l="ENG"><s0>Involuntary movement</s0><s5>41</s5></fC07><fC07 i1="10" i2="X" l="SPA"><s0>Movimiento involuntario</s0><s5>41</s5></fC07><fC07 i1="11" i2="X" l="FRE"><s0>Trouble neurologique</s0><s5>42</s5></fC07><fC07 i1="11" i2="X" l="ENG"><s0>Neurological disorder</s0><s5>42</s5></fC07><fC07 i1="11" i2="X" l="SPA"><s0>Trastorno neurológico</s0><s5>42</s5></fC07><fC07 i1="12" i2="X" l="FRE"><s0>Aminoacide excitateur</s0><s5>43</s5></fC07><fC07 i1="12" i2="X" l="ENG"><s0>Excitatory aminoacid</s0><s5>43</s5></fC07><fC07 i1="12" i2="X" l="SPA"><s0>Aminoácido excitador</s0><s5>43</s5></fC07><fC07 i1="13" i2="X" l="FRE"><s0>Neurotransmetteur</s0><s5>44</s5></fC07><fC07 i1="13" i2="X" l="ENG"><s0>Neurotransmitter</s0><s5>44</s5></fC07><fC07 i1="13" i2="X" l="SPA"><s0>Neurotransmisor</s0><s5>44</s5></fC07><fN21><s1>269</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Canada</li><li>Italie</li><li>États-Unis</li></country><region><li>Maryland</li></region></list><tree><country name="Canada"><noRegion><name sortKey="Samadi, Pershia" sort="Samadi, Pershia" uniqKey="Samadi P" first="Pershia" last="Samadi">Pershia Samadi</name></noRegion><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bedard">Paul J. Bedard</name><name sortKey="Gregoire, Laurent" sort="Gregoire, Laurent" uniqKey="Gregoire L" first="Laurent" last="Gregoire">Laurent Gregoire</name><name sortKey="Guidetti, Paolo" sort="Guidetti, Paolo" uniqKey="Guidetti P" first="Paolo" last="Guidetti">Paolo Guidetti</name><name sortKey="Samadi, Pershia" sort="Samadi, Pershia" uniqKey="Samadi P" first="Pershia" last="Samadi">Pershia Samadi</name></country><country name="États-Unis"><region name="Maryland"><name sortKey="Rassoulpour, Arash" sort="Rassoulpour, Arash" uniqKey="Rassoulpour A" first="Arash" last="Rassoulpour">Arash Rassoulpour</name></region><name sortKey="Schwarcz, Robert" sort="Schwarcz, Robert" uniqKey="Schwarcz R" first="Robert" last="Schwarcz">Robert Schwarcz</name></country><country name="Italie"><noRegion><name sortKey="Izzo, Emanuela" sort="Izzo, Emanuela" uniqKey="Izzo E" first="Emanuela" last="Izzo">Emanuela Izzo</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000800 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000800 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:05-0387176
|texte= Effect of kynurenine 3-hydroxylase inhibition on the dyskinetic and antiparkinsonian responses to levodopa in parkinsonian monkeys
}}
| This area was generated with Dilib version V0.6.29. |  |